Access Program Information
The purpose of this sub-study is to provide expanded access of AZEDRA (Ultratrace Iobenguane
I 131) and to evaluate the safety and tolerability of AZEDRA in subjects with
iobenguane-avid malignant and/or recurrent pheochromocytoma/paraganglioma (PPGL).